Will this deal lead to Mankind Pharma focusing on exports too?
We have been very clear from the beginning that we don't want to get into exports with generic or me-too products. We always wanted products with a high level of entry barriers and complexity.
With the BSV deal, we now have branded products in some cases, there is no competition, and in others, there is limited competition (one or two players). For example, consider the AntiD product that BSV hasnearly 5-7 per cent of Indian mothers are Rh negative (blood group), which amounts to 8-10 million mothers.
Lack of preventive measures can cause brain damage or jaundice in & newborns. The mother needs to take a dose in the third trimester and within 72 hours after delivery with an Rh-positive child. Only 3040 per cent of expecting mothers adhere to this due to lack of awareness. BSV has the world's first and only recombinant for AntiRhoD, which has a valid patent until 2028. It also has vertically integrated in-house cell lines. If anyone tries to make any product of BSV, it would take five to 10 years at least. But we also feel there is huge potential for these products in the Indian market itself. Even after acquiring BSV, 87 per cent of the revenues of the entity will come from India. Wherever we have strong opportunities in the rest of the world, we will pursue them. Our ambition is to become a great company in India.
How do you wish to grow the synergies between BSV and Mankind?
Probably the fastest-growing therapy segment is infertility treatment. People are marrying late, then deciding to have a baby later on in their lives, focusing on careers, stress-myriad factors are affecting fertility.
Esta historia es de la edición July 29, 2024 de Business Standard.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición July 29, 2024 de Business Standard.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
IT stocks suffer biggest one-day fall in six weeks
Accenture promotion delay, past Fed rate cuts cited
Cabinet clears 'One Nation, One Poll' and host of proposals in farm to space
Soon after completing 100 days in office, the National Democratic Alliance (NDA) government has taken a series of decisions that would have political and economic implications for the country.
Tata Power to scale up internal RE component supply chain
Plans to manufacture key parts rather than buying them
IT staffers' FY25 salary hikes may be 5.5-8%
Experts say top performers may continue to see increases ranging from 12-18%
RInfra pares debt by 87% to ₹475 cr
Anil Ambani group firm Reliance Infrastructure (RInfra) and its subsidiary Reliance Power (RPower) have cleared a major part of their debt, with RInfra reducing its standalone external borrowing by almost 87.6 per cent to ₹475 crore, down from ₹3,831 crore as on June, according to stock exchange notices.
'No plans to phase out Kwid until rules allow'
Renault India, which saw a 33 per cent decline in sales in 2023, is facing a challenging 2024. The company's Managing Director and Chief Executive Officer VENKATRAM MAMILLAPALLE, discusses the firm's revival plans, launch strategy, and the future of the Kwid in an interaction with Shine Jacob in Chennai. Edited excerpts:
25-year-old company veteran Samir Kumar has cart full as he takes reins at Amazon India
Amazon has announced that Samir Kumar, a 25-year veteran of the company, will assume the role of head of its India consumer business effective October 1, 2024.
ZEEL refutes $940 mn Disney Star claim over ICC TV rights deal
Star India on Monday filed a statement of case seeking $940 million damages from Zee Entertainment Enterprises (ZEEL) over the terminated ICC TV rights deal, the latter said in a stock exchange filing.
Best option is to double down on mkt strategy: P&G India
Procter & Gamble Hygiene and Healthcare (PGHH) and Gillette India (GI), both listed entities of Procter & Gamble India, noted in their investor calls that despite near-term macroeconomic challenges, an above normal monsoon will help revive demand in India.
'Irreparable loss for us': EY India on death of CA
The death of 26-year-old chartered accountant Anna Sebastian Perayil is \"tragic\" and an \"irreparable loss\" for EY India, the company said in a statement on Wednesday.